---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-216168"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:45:13.104942+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inovio reports Q2 net loss $108.5M, extends cash runway into Q3 2024 via restructuring; appoints new CMO

## Summary
- Net loss $108.5M ($0.46 per share) vs $82.1M loss a year ago; revenue $784K (up from $273K).
- Operating expenses $104.9M, up from $83.5M; includes $14M non-cash litigation settlement and $6.9M severance.
- Cash & investments $348.1M at June 30; expects cash burn ~$73M in Q3, runway into Q3 2024.
- Restructuring: 18% workforce reduction, 86% contractor cut; expects 30% OpEx reduction; $1.6M charge in Q3.
- Appointed Dr. Michael Sumner as CMO; positive Phase 1/2 data for INO-5401 in GBM at ASCO.

## SEC filing metadata
- accession: 0001193125-22-216168
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312522216168/0001193125-22-216168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312522216168/d373738d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-216168
- JSON: https://secwatch.observer/filing/0001193125-22-216168.json
- Plain text: https://secwatch.observer/filing/0001193125-22-216168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.